Kidney Function Decline in Sickle Cell Disease
In this large, real-world cohort of patients with SCD, RASi use was not associated with slowed eGFR decline. These findings underscore the limitations of observational data and highlight the urgent need for prospective trials to identify effective GFR-preserving therapies for this high-risk population.
Authors
- Kabir O. Olaniran (ORCID: https://orcid.org/0000-0002-1785-960X)
- Robert D. Toto
- Orson W. Moe
- Alecia Nero
- S. Susan Hedayati
Institutions
- Southwestern Medical Center (US)
- Stony Brook University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Kidney360
- Published
- 2026-01-21
- DOI
- https://doi.org/10.34067/kid.0000001116
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00